"On behalf of the board and all our employees, I want to thank Alvin for his tremendous contributions to the rapid progression of our pipeline," said Mr. Aselage. "Alvin is leaving us in a strong position to continue the advancement of sparsentan and RE-024; we wish him success in his new role."
"While I am sad to leave Retrophin, I'm incredibly proud of the progress we have made towards delivering new therapies for rare disease patients," said Dr. Shih. "I look forward to contributing to Retrophin's future success as an external advisor."
About Retrophin
Retrophin is a fully integrated biopharmaceutical company dedicated to delivering life-changing therapies to people living with rare diseases who have few, if any, treatment options. The
Company's approach centers on its pipeline featuring clinical-stage assets targeting rare diseases with significant unmet medical needs, including sparsentan for focal segmental glomerulosclerosis (FSGS), a disorder characterized by progressive scarring of the kidney often leading to end-stage renal disease, and RE-024 for pantothenate kinase-associated neurodegeneration (PKAN), a life-threatening neurological disorder that typically begins in early childhood. Research exploring the potential of early-stage assets in several rare diseases is also underway. Retrophin's R&D efforts are supported by revenues from the Company's commercial products Thiola®, Cholbam® and Chenodal®.
Retrophin.com
Contact:
(Investors)
Chris Cline, CFA
Senior Director, Investor Relations
646-564-3680
IR@retrophin.com
Source:
Retrophin, Inc.
News Provided by Acquire Media